Natural killer cell

Verismo Therapeutics Appoints Steven Albelda, MD, to Scientific Advisory Board

Retrieved on: 
Tuesday, November 9, 2021
University, Lung cancer, National Virtual Translation Center, United States Air Force Scientific Advisory Board, Therapy, MD, Verismo, Mesothelioma, Disease, Technology, NCI, Immunotherapy, CAR, Tumor microenvironment, Clinical trial, II, Perelman School of Medicine at the University of Pennsylvania, Neoplasm, Journal of Thoracic Oncology, Natural killer cell, Gene editing, Penn, Patient, Ill, Pharmaceutical industry, Vaccine

PHILADELPHIA, Nov. 9, 2021 /PRNewswire/ -- Verismo Therapeutics, Inc ., a recent Penn spin-out behind a novel multichain KIR-CAR platform technology for CAR T-cells, today announced the appointment of a leading pulmonologist and gene therapy clinician, Steven M. Albelda, MD, to its Scientific Advisory Board.

Key Points: 
  • PHILADELPHIA, Nov. 9, 2021 /PRNewswire/ -- Verismo Therapeutics, Inc ., a recent Penn spin-out behind a novel multichain KIR-CAR platform technology for CAR T-cells, today announced the appointment of a leading pulmonologist and gene therapy clinician, Steven M. Albelda, MD, to its Scientific Advisory Board.
  • "It is a great privilege to have Dr. Albelda join our Scientific Advisory Board," stated Dr. Bryan Kim, Chief Executive Officer at Verismo.
  • We are excited to see his great contribution to Verismo's mission to eradicate solid tumors in terminally ill patients."
  • Verismo Therapeutics is a pioneer in multichain KIR-CAR T technology, on track to bring its first asset into First-in-Human clinical trials in 2023.

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting

Retrieved on: 
Wednesday, October 27, 2021
Natural killer cell, Albert Einstein College of Medicine, Breast cancer, ADNI, Research, Cancer, Disease, Lists of diseases, Degenerative disease, Leukemia, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, Cytokine, Ovarian cancer, Multiple myeloma, Neuroinflammation, TNF, White matter, Brain, Marketing, Inflammation, Company, Biomarker, Clinical trial, COVID-19, NK, AD, Cell, NASH, GLOBE, Process control block, Lymphoma, Pharmaceutical industry, Medical imaging, Vaccine

Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.

Key Points: 
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • INmune Bio has two product platforms that are both in clinical trials.
  • Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

Retrieved on: 
Monday, October 25, 2021
Natural killer cell, Research, Cancer, PIN, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, TNF, Marketing, Inflammation, Company, COVID-19, NASH, Pharmaceutical industry

A replay will also be available through November 10 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no.

Key Points: 
  • A replay will also be available through November 10 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.
  • The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Global Natural Killer Cell Therapies Pipeline Insight Report 2021: 100+ Companies and 140+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Health, Pharmaceutical, ALECSAT, Head, Cell, Myelodysplastic syndrome, Lymphatic system, Squamous cell carcinoma, II, Immune system, AML, Cancer, Large-cell lung carcinoma, Breast cancer, CD8, Discovery, CDK, Chronic lymphocytic leukemia, GMP, CD122, MDS, Therapy, Natural killer T cell, Umbilical cord, HIV, ALL, Clinical trial, News, IPH2201, Multiple myeloma, Bladder cancer, Acute myeloid leukemia, Phase II, NK, Natural killer cell, MM, Mergers and acquisitions, TILS, Acute lymphoblastic leukemia, III, ADCC, Pharmaceutical industry, Vaccine

This "Natural Killer Cell Therapies - Pipeline Insight, 2021" report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape.

Key Points: 
  • This "Natural Killer Cell Therapies - Pipeline Insight, 2021" report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer Cell Therapies R&D.
  • The therapies under development are focused on novel approaches to treat/improve Natural Killer Cell Therapies.
  • This segment of the Natural Killer Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Hoag First Hospital in Orange County to Enroll Patients in NK Cell Therapy Clinical Trial for Triple-Negative Breast Cancer Patients

Retrieved on: 
Thursday, October 14, 2021
Top 10 (comics), American Cancer Society, Hospital, Gaps, Metastasis, Breast, Heart, BRCA1, Cancer, Breast cancer, Natural killer T cell, Natural killer cell, Trial of the century, American Nurses Credentialing Center, Woman, Triple-negative breast cancer, Transport, Education, Mutation, ANCC, Multimedia, Health, Patient, Elective surgery, Hoag, Research, Mental health, Toxicity, Recurrence, NK, Immunotherapy, Neuroscience, Safety, Sacituzumab govitecan, Hoag (health network), Quality of life, Pharmaceutical industry, Medical imaging

Hoag is the first and only site in Orange County enrolling patients in the study.

Key Points: 
  • Hoag is the first and only site in Orange County enrolling patients in the study.
  • Participants are triple negative breast cancer patients who have at least two prior treatments for metastatic disease.
  • Hoag is involved in a variety of cell therapy trials evaluating "natural killer," or NK cell therapy , which has proven to be beneficial in treating solid tumors.
  • Triple negative breast cancers are a more aggressive form of breast cancer and until recently have lacked specific targets for personalized therapy.

Verismo Therapeutics Appoints Laura Johnson, Ph.D. as Chief Scientific Officer

Retrieved on: 
Wednesday, October 13, 2021
Leadership, Duke University, Verismo, GBM, Technology, Syngenic, Assistant professor, Penn Center, Doctor of Philosophy, Cancer, Development, CAR, Penn, Patient, Research, Gene editing, Glioblastoma, Translational medicine, University, Natural killer cell, NIH, HLB, Drug, Therapy, Pharmaceutical industry

PHILADELPHIA, Oct. 13, 2021 /PRNewswire/ -- Verismo Therapeutics, Inc ., a recent Penn spin-out behind a novel multichain KIR-CAR platform technology for CAR T-cells, today announced the appointment of a leading tumor-immunologist and gene-engineered T-cell therapy pioneer, Laura A. Johnson, M.Sc, Ph.D., as its Chief Scientific Officer.

Key Points: 
  • PHILADELPHIA, Oct. 13, 2021 /PRNewswire/ -- Verismo Therapeutics, Inc ., a recent Penn spin-out behind a novel multichain KIR-CAR platform technology for CAR T-cells, today announced the appointment of a leading tumor-immunologist and gene-engineered T-cell therapy pioneer, Laura A. Johnson, M.Sc, Ph.D., as its Chief Scientific Officer.
  • "We are delighted to have Laura join the Verismo team," stated Bryan Kim, D.M.D., Chief Executive Officer at Verismo.
  • "Laura brings over 20 years of leadership in the field of gene-engineered cell therapy research and development targeting solid tumors and stands among the scientific founders of the KIR-CAR platform.
  • Her experience developing the KIR-CAR platform alongside Verismo co-founder, Dr. Michael Milone, at Penn is invaluable, and we look forward to seeing her make her mark at Verismo."

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

Retrieved on: 
Monday, September 27, 2021
Interest, Security (finance), Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, TNF, Cancer, Patient, Natural killer cell, Marketing, NASH, Company, Disease, COVID-19, Inflammation, Research, Doctor of Philosophy, GLOBE, Treatment, Pharmaceutical industry

is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Key Points: 
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers and Treatment Resistant Depression(Xpro), and NASH (LIVNate).
  • Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research

Retrieved on: 
Wednesday, September 22, 2021
NGM, Translational research, Diagnosis, 23andMe, Translation, GSK, Therapy, Health, Joint Genome Institute, Alice, Natural killer cell, Patient, Nature, California Institute of Technology, CEO, Leadership, GNF, Stanford University, Genomics, Cell, Drug discovery, Doctor of Philosophy, BS, Pharmaceutical industry

SHANGHAI, Sept. 22, 2021 /PRNewswire/ --Asieris Pharmaceuticals announced the appointment of Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect from September 20, 2021.

Key Points: 
  • SHANGHAI, Sept. 22, 2021 /PRNewswire/ --Asieris Pharmaceuticals announced the appointment of Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect from September 20, 2021.
  • Alice has over 20 years of experience in the US pharmaceutical/biotech industry with a successful track record in drug discovery and translational research.
  • Previously, she served asa Research Fellow at 23andMe Inc. in California, where she built up a biology team and led 23andMe's internal and joint drug discovery effort with GSK in the oncology area.
  • Alice received her PhD in Neuroscience from Stanford University, and BS in Biology from California Institute of Technology.

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Monday, September 20, 2021
BOCA, Security (finance), Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, TNF, Cancer, Patient, Natural killer cell, Limor Livnat, MD, Marketing, NASH, CEO, Company, Disease, COVID-19, Inflammation, Research, Oppenheimer, GLOBE, Pharmaceutical industry

Please contact your representative at Oppenheimer or Cantor Fitzgerald to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.

Key Points: 
  • Please contact your representative at Oppenheimer or Cantor Fitzgerald to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

Retrieved on: 
Wednesday, September 1, 2021
Company, Neurodegeneration, Private Securities Litigation Reform Act, Inflammation, Cancer, U.S. Securities and Exchange Commission, TNF, Treatment, Research, Natural killer cell, Marketing, NK, NASDAQ, Patient, Brain, COVID-19, Technology, Security (finance), Pharmaceutical industry

Boca Raton, FL, Sept. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that XPro™ (pegipanermin), the Company’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease (AD), treatment resistant depression, and other neurological diseases where neuroinflammation is implicated, has been found to decrease multiple species of Phospho Tau (pTau) and improve neuroimaging biomarkers of myelination in patients with AD.

Key Points: 
  • Xpro could have substantial beneficial effects in patients with Alzheimers and other neurodegenerative diseases by decreasing neuroinflammation.
  • For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bios website.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • DN-TNF is currently being developed for COVID-19 complications (Quellor), cancer (INB03), Alzheimers and Treatment Resistant Depression(Xpro).